With the help of robots and artificial intelligence, our manufacturing sites are becoming smarter so medicines and vaccines can reach patients faster. Advanced technology increases production capacity by 25-40% and reduces lead times by 15-20%, allowing more batches of medicines to be made. Digitalisation detects early signs of fault, ensuring no crucial steps are missed and reducing human error. Plus, essential resources are reduced, making the whole process greener. Read our article to find out why investing in technology right across our business helps us deliver the best outcomes for patients: https://gsk.to/3MihB41
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brentford, Middlesex
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
GSK reposted this
Samfunnet får opptil 19 ganger tilbake for hver krone som brukes på vaksinasjon mot influensa, pneumokokksykdom, helvetesild og RSV 💡 #osloeconomics har beregnet at de fire sykdommene medføre 39,9 milliarder kroner i tapt helse, 15,9 milliarder kroner i tapt produksjon og 1,2 milliarder kroner i økte helsetjenestekostnader i Norge i 2030. 📉 👇 Socio-Economic Value of Adult Immunisation Programmes, april 2024 https://shorturl.at/D5M4H Oslo Ecomomics, oktober 2023 https://shorturl.at/xcNB5 Vi har ikke råd til å la være å #forebygge sykdom 🧡 #folkehelse #voksenvaksinasjonsprogram #vaksinasjon
Les mer på sykdomsinfo.no
-
#News for #Investors and #Media: Today, we announced that the FDA has approved an expanded indication of our immuno-oncology cancer therapy in the US. Learn more: https://gsk.to/46xrbZK
-
We’re passionate about helping more patients enjoy a better quality of life. Did you know an estimated 315 million people around the world are thought to be affected by COPD? That’s chronic obstructive pulmonary disease. And this figure is expected to increase by 2040. Recognising the symptoms and opening up to a healthcare professional about your breathing difficulties can mean you get help to prevent them worsening. #COPD #AheadTogether
-
News for #Investors and #Media This morning we announced our strong Q2 2024 performance. Swipe to see our key highlights. For more insights, visit us at https://gsk.to/3YqcnKr. $GSK
-
As our momentum this year continues, our CEO Emma Walmsley shared her reflections on our Q2 2024 results. Read more ⤵
News for #Investors and #Media I’m delighted to announce GSK’s results for Q2 2024. Our momentum continues with sales up 13%, core operating profit up 21% and core earnings per share up 17%*. And we are raising our full year guidance. This excellent performance reflects strong operational execution and the strengthening breadth of our portfolio of medicines and vaccines, to both prevent and treat disease. Sales of our Specialty Medicines grew 22% and particularly benefited from new product launches in oncology and HIV. And we continue to make good progress in R&D. So far this year we’ve secured approvals or filings for 10 major opportunities and reported positive data from 7 phase III trials. We have also strengthened our capabilities in key technology platforms and completed investments to develop new mRNA vaccines, ultra-long-acting HIV medicines, and promising new respiratory treatments. Enormous thanks to the many people inside and outside GSK who are making this happen. Because when we grow, we’re helping more people with our innovative vaccines and medicines – which is what we’re all here for. #AheadTogether *all excluding COVID solutions and at CER
-
-
News for #Investors and #Media Explore our Q2 2024 figures at a glance. https://www.gsk.com/en-gb/. $GSK
-
-
News for #Investors and #Media Watch our CEO Emma Walmsley as she shares our Q2 results, with continued strong performance and upgraded full-year guidance for 2024. For more, visit https://www.gsk.com/en-gb/ $GSK #Q2Results
-
#Investors and #Media Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our Q2 2024 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For investors: https://gsk.to/3LJ8b0W
-
“Science is giving us all these solutions to prevent disease before it even starts, but if we don't have the right policies in place to unlock funding, make access easy for people and build the belief, the right education, what does it matter?” Read The New York Times' interview with Kate Hashey, MA, MPH about how prioritizing #prevention and ensuring access to #vaccines for everyone is part of GSK’s vision to improve #publichealth around the globe 🌎➡️ https://gsk.to/3yog60x